AsclepiX Therapeutics: Private, ophthalmology focused early stage company; technology out of Johns Hopkins. Lead compound AXT107: novel peptide, inhibiting VEGF and activating Tie2 is the only therapeutic in clinical development for DME and wet AMD that was identified through a process of Artificial Intelligence, mining the human proteome for cryptic anti angiogenic and homeostatic peptides, rather than through a standard drug development process. AXT107 demonstrated efficacy and durability in rabbit and mouse models that is superior to standard of care Eyelea. Planning mid 2020 IND submission and 3Q20 Ph1/2 initiation (DME and wetAMD).
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Pre-Clinical Stage
Disease Space
Ophthalmology
Listing
Private
Website:
Address:
301 West 29th Street
Suite 2004
Baltimore, MD 21211
United States

Company Participants at AsclepiX Therapeutics KOL Lunch New York

  • Wendy Perrow, MBA, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Solebury Trout Management Access Event

San Francisco, CA, United States, January 13 – January 16, 2020